New Molecular Advances in Lung Cancer

Dear Colleagues,

The treatment of advanced non-small-cell lung cancer has developed in rapid and exciting ways over the last 20 years.

In particular, the importance of identifying molecular activating oncogenes, whose presence may decide treatment with target inhibitors, is well established, bringing better outcomes with good compliance and quality of life. Up till now, for patients affected by advanced non-squamous non-small-cell lung cancer, it is important to identify one of ten activating oncogenes at diagnosis to find the right systemic treatment; furthermore, the mutation has to be confirmed before progression, with consideration of the likelihood of resistance.

In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following:

1. Advances in the EGFR pathway, common and uncommon mutations;
2. Advances in the RET pathway;
3. Advances in the BRAF pathway, common and uncommon mutations;
4. Advances in the KRAS pathway;
5. Advances in the MET pathway;
6. The role of immune checkpoint inhibitors in oncogene-addicted patients;
7. Pharmacological interactions with tyrosine kinase inhibitors;
8. Cardiac toxicity with tyrosine kinase inhibitors;
9. Advances in the ALK pathway;
10. The role of radiotherapy in the management of oncogene-addicted disease.

We look forward to receiving your contributions.

Prof. Dr. Alessandra Bearz
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• lung cancer
• oncogene
• tyrosine kinase inhibitors